Recent News and Articles on the Keywords: women + cervical + testing  Related to the article below (Last Update: 8/7/2008)

Is this normal ovulation? Or it is a sign of cervical cancer? Daily Monitor, Uganda - Every woman who is sexually active or more than 18 years should carry out a PAP smear as a routine test to rule out the cancer which if caught early will be ... German Association of Gynecology and Obstetrics Recommends HPV ... MarketWatch - Aug 4, 2008 "Unlike other cancers, cervical cancer is virtually 100 percent preventable -- if women and their healthcare providers have access to the HPV Test and other ... RTE.ie Harney announces cervical vaccine programme Irish Times, Ireland - Aug 5, 2008 About 85 women die from cervical cancer in Ireland each year, but about 2000 potential cases are diagnosed through smear testing. ... Modern medicine Cancer prevention vs public policy La Voz Nueva all 30 news articles » Los Angeles Times Breast cancer screenings: How soon to start? WRAL.com, NC - Her mother is a two-time breast cancer survivor and has also had cervical cancer. Only 5 to 10 percent of breast cancer cases are inherited, which means a ... Breast cancer: What you need to know Food Consumer all 7 news articles » Cancer: World`s worst killer Triumph, Nigeria - According to TACS, ovarian cancer is more likely to occur in women who have never had children, or have their first child after age 30. Cervical cancer ... Mass male circumcision vital in HIV prevention New Vision, Uganda - All the three studies established that male circumcision provided up to 60% protection against HIV transmission from women to men. The foreskin of the penis ... In pursuit of Excellence in Journalism IPPmedia, United Republic of Tanzania - Aug 2, 2008 WAACC wants the government to develop a policy that will compel women who seek other services at health units to test for cervical cancer as well. ... Vitamin C jabs may combat cancer New Scientist (subscription), UK - Aug 5, 2008 That trial, led by Jeanne Drisko of the University of Kansas in Kansas City, aims to recruit 50 women to test the safety of giving intravenous vitamin C, ... Measuring Cancer Therapy Success With Oxygen Science Daily (press release) - Aug 5, 2008 In their study of 88 women with cervical cancer, Dr. Wang and his colleagues measured the level of hemoglobin, the oxygen-carrying molecule in blood, ... Pattaya People Women?s Health: Thin Prep Pattaya People, Thailand - Jul 31, 2008 The "Thin Prep" cervical smear test is a newer, more sensitive method of detecting pre-cancerous cervical cells. In a thin prep, the smear test that a woman ...

HPV DNA testing is a cost-effective strategy for women with equivocal cervical screening results

A study has found that using human papillomavirus ( HPV ) DNA testing to determine who should receive a cervical examination called colposcopy is a cost-effective management strategy for women with equivocal Pap test results known as ASCUS ( atypical squamous cells of undetermined significance ).

About 5% of all Pap tests result in a diagnosis of ASCUS; however, only about 10% of women with this abnormality actually have precancer or cancer.
The ASCUS and low-grade squamous intraepithelial lesions ( LSIL ) triage study ( ALTS ) was launched in the late 1990s to determine the best management strategy for women with these Pap test abnormalities that would both maximize the detection of clinically significant disease and reduce the need for unnecessary office visits and procedures.
Results from ALTS, published in 2003, found that referring only those women with a positive HPV test to colposcopy was as effective at detecting cervical precancer or cancer as referring all women to colposcopy.

Shalini L. Kulasingam, of the Duke Center for Clinical Health Policy Research, and colleagues used data from 3488 women with ASCUS enrolled in ALTS to study the cost-effectiveness of three management strategies studied in ALTS, immediate colposcopy, HPV DNA testing, or conservative management with repeat Pap tests at 6-month intervals.

They found that the cost associated with HPV DNA testing was acceptable given the number of precancers and cancers found by this strategy.
HPV DNA testing was less costly and detected more cases of precancer than immediately sending all women to receive colposcopy.
The least costly strategy was a single repeat Pap test with referral to colposcopy for only those women with a high grade Pap test result; however, this option detected the fewest cases of precancer.
The researchers concluded that HPV DNA testing for women with ASCUS is cost-effective and therefore, economically viable.

In an accompanying editorial, Joy Melnikow, of the University of California-Davis in Sacramento, and Stephen Birch, of McMaster University in Ontario, wrote that despite the analysis by Kulasingam, et al., HPV DNA testing for the 3 million women a year diagnosed as ASCUS would require an overall total of $250 million dollars a year. Such money, in addition to money saved by reducing overscreening for cervical cancer, could instead be used to screen for cervical cancer and precancer in underscreened populations, particularly women who have little access to health care.

Source: Journal of the National Cancer Institute, 2006